A Randomised Open Controlled Parallel Group Study Comparing Norspan and Tramadol

• Status: Completed
• Trial end date: 2007-06-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the efficacy and safety of Norspan versus Tiperol Retard among OA patients who are sub-optimally treated with current analgesic. Those patients may benefit from treatment with a long lasting analgesic.

• Phase: Phase 4

Details

• Lead Sponsor: Mundipharma AB
• Treatments: Tramadol

Criteria

Inclusion Criteria:

• OA diagnosis

• BS11 greater than or equal to 4 at base line

• Not adequately pain relieved with 4,000 mg paracetamol daily

Exclusion Criteria:

• Treated with high potent opioids for their OA pain

• Treated with a regular dose for greater than one week of Tramadol, Codeine or dextropropoxifene during the last three months

• Other chronic conditions requiring frequent analgesic therapy